It’s laden with unmet need and potentially one of the largest and fastest-growing pharmaceutical markets in the world. Unfortunately pharmaceutical manufacturers have found osteoporosis a very difficult disease to treat satisfactorily. After years of mostly “me toos” and slightly tweaked versions of old standbys, a few highly promising compounds are finally in the wings. Will they revitalize the market or just bring their own baggage with them?
The cost of fractures in the U.S. alone is approximately $15 billion to $20 billion, according to OptumInsight VP Steve Clark. The International Osteoporosis Foundation, meanwhile, says an estimated 200 million people are affected by the disease globally. IMS values the U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?